1. Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer

3. Overview of Metastatic TNBC

4. Case 1: Introduction

5. OlympiAD: Olaparib in Patients With mBC and Germline BRCA Mutations

6. EMBRACA: Talazoparib in Patients With mBC and Germline BRCA Mutations

7. Using PARP Inhibitors in BRCA-Mutated MBC

8. Case 2: Introduction

9. First-Line Treatment of mTNBC IMpassion130: Nab-Paclitaxel + Atezolizumab

10. Testing for PD-L1 in Patients With TNBC

11. Considerations With Checkpoint Inhibitors

12. Treatment of PD-L1-Negative, Germline BRCA-WT mTNBC

13. What About Chemotherapy Doublets? Expert Perspectives

14. What If Patients Are PD-L1-Positive and Germline BRCA Mutation-Positive?

15. Second- and Third-Line Treatment of mTNBC

16. Making Treatment Decisions in mTNBC

17. Considering Clinical Trials in mTNBC

18. Future Directions in mTNBC: Antibody-Drug Conjugates

19. Future Directions in mTNBC: Other Approaches

20. Shared Decision-Making Principles

21. Direct Patients to Reputable Resources

22. Key Takeaways

23. Abbreviations

24. Abbreviations (cont)